Stories about Therapie

Technische Universität München

A repair program for the heart

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37376 Images: https://mediatum.ub.tum.de/1658419 NEWS RELEASE A repair program for the heart Cardiac progenitor cells generate healthy tissue after a heart attack Following a heart attack, the human body is incapable of repairing lost tissue due to the heart’s ...

Technische Universität München

Overcoming resistance of pancreatic cancer to immunotherapies

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37173 High resolution images: https://mediatum.ub.tum.de/1641984 NEWS RELEASE “Inflaming” cold tumors Overcoming resistance of pancreatic cancer to immunotherapies Pancreatic carcinoma is a ...

Sysmex Inostics GmbH

University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients

Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...

Technische Universität München

A medication against SARS-CoV-2 – new strategy also promises protection against future SARS-CoV-2 variants

TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37076 High resolution images: https://mediatum.ub.tum.de/1637268 NEWS RELEASE A medication against ...

Almirall, S.A.

Almirall delivers solid nine months 2021 results and tightens its upgraded guidance

Barcelona, Spain (ots/PRNewswire) - - Strong Core business performance with growth in Core Net Sales EUR601.7 MM (+6.2% year-on-year) and Core EBITDA reaching EUR164.2 MM, (+20.3% year-on-year) driven by positive contribution from Growth Drivers and a strong EU dermatology performance - Key Growth Drivers underpinning increase in Core Net Sales. Strong performance from ...

ISMST

Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries

Vienna (ots) - Success Story of Extracorporeal Shock Wave Therapy (ESWT) Successful for over 40 years in urology for the disintegration of kidney stones, with high efficiency and hardly any side effects worth mentioning. How does the shock wave work? Without causing mechanical damage, shockwaves trigger a biological ...

Sysmex Inostics GmbH

New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

Almirall, S.A.

Almirall S.A.: Experts highlight the need to focus on psoriasis patients' wellbeing in clinical practice

Barcelona, Spain (ots/PRNewswire) - - Psoriasis affects the overall emotional wellbeing of 88% of patients[1], and at least 20% of psoriasis patients have considered suicide[2] - Currently used endpoints in psoriasis do not capture the full impact of this skin condition on patients' lives, and almost 50% of them ...

Almirall, S.A.

Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials

Barcelona (ots/PRNewswire) - - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Lebrikizumab led to significant improvements with ...

Helmholtz Zentrum München

Gastrulation research reveals novel details about embryonic development

Sysmex Inostics GmbH

Sysmex Inostics presents data at ASCO

Baltimore, MD (ots) - Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial. Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution for oncology, is presenting the poster ...

BrainRepair UG

Investment breakthrough for BrainRepair UG start-up – Stem cell treatment for newborns / Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15M

Fördergesellschaft IZB mbH

2

Lindis Biotech develops immunotherapy against bladder cancer

Sysmex Inostics GmbH

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients

Baltimore, MD, USA (ots) - Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster “Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients” at the 112th Annual Meeting of the American Association for Cancer ...

Fördergesellschaft IZB mbH

3

World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools

Semdor Pharma Group

Merger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabis

Technische Universität München

Breathing rate predicts therapeutic benefits for heart patients

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36385/ NEWS RELEASE Discovering a forgotten biosignal Breathing rate predicts therapeutic benefits for heart patients Conditions causing arrhythmia are among ...

Sysmex Inostics GmbH

Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel" at ...

BrainRepair UG

Regulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan

Sysmex Inostics GmbH

Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...

Sysmex Inostics GmbH

Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...

Carl Zeiss Meditec AG

Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed

Jena, Germany (ots) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published [1] Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when ...

Sysmex Inostics GmbH

Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing

Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...

Versameb AG

Versameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials

Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...

SYNformulas GmbH

2

Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation

eleva GmbH

Eleva's drug candidate to be examined for use in Covid-19 treatment

Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...

Helmholtz Zentrum München

2

Beta cells from stem cells: Potential for cell replacement therapy

Elastrin Therapeutics

Elastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients

Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...

Sysmex Inostics GmbH

Sysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing

Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...

Sysmex Inostics GmbH

Sysmex Inostics and Oxford Gene Technology plasma and tissue sequencing show clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment

Hamburg, Germany and Baltimore, Maryland (ots) - Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the clearance of circulating tumor DNA (ctDNA) in HER2-positive or triple-negative breast cancer patients undergoing ...